-
6 days ago | 
ajmc.com | Melinda Buntin |Christina Mattina
Am J Manag Care. 2025;31(6):In Press_____AJMC: How have the concept of managed care and the conversations around it changed over the past 30 years? BUNTIN: It’s really fun to think about this and realize how far we’ve come.
-
1 month ago | 
ajmc.com | Christina Mattina
AJMC: How have the concept of managed care and the conversations around it changed over the past 30 years? O’BRIEN: Over my 30 years in health care, I’ve seen managed care go from being a derogatory term that referred to stinting on care to achieve PMPM [per-member per-month] savings to being a movement that embraced better health, better care, and lower total health care costs.
-
1 month ago | 
ajmc.com | Christina Mattina
The FDA Wednesday approved nipocalimab-aahu (Imaavy; Johnson & Johnson) for the treatment of generalized myasthenia gravis (gMG) in adults and pediatric patients 12 years or older who are anti–acetylcholine receptor (AChR) or anti–muscle-specific kinase (MuSK) antibody positive.1 The approval of the FcRn-blocking monoclonal antibody, which works by reducing immunoglobulin G (IgG), was supported by data from the ongoing Vivacity-MG3 study.
-
1 month ago | 
ajmc.com | Julia Bonavitacola |Christina Mattina
John Michael O'Brien, PharmD, MPH, president and CEO of the National Pharmaceutical Council (NPC), discussed how the current administration could focus on the Inflation Reduction Act, pharmacy benefit managers (PBMs), and the 340B program to help patients with the rising cost of health care. This transcript was lightly edited for clarity; captions were auto-generated.
-
1 month ago | 
ajmc.com | Julia Bonavitacola |Christina Mattina
John Michael O'Brien, PharmD, MPH, president and CEO of the National Pharmaceutical Council, discussed how managed care will change in the upcoming years, with employers being more engaged in the area than ever before. This transcript has been lightly edited for clarity; captions are auto-generated. TranscriptWhat changes do you see taking place in managed care over the coming years?
-
1 month ago | 
ajmc.com | Julia Bonavitacola |Christina Mattina
John Michael O'Brien, PharmD, MPH, a member of AJMC’s editorial board and the president and CEO of the National Pharmaceutical Council (NPC), spoke about how he believes managed care has changed since The American Journal of Managed Care® first published in 1995. This transcript has been lightly edited for clarity; captions are auto-generatedTranscriptHow has the concept of managed care and the conversations around it changed over the past 30 years?
-
1 month ago | 
ajmc.com | Christina Mattina
First catheters, now skin substitutes—and more areas of anomalous medical billing will continue to pop up, requiring data vigilance and collaboration on the part of accountable care organizations (ACOs), according to speakers at the National Association of ACOs (NAACOS) Spring 2025 Conference. The identification of these areas potentially signaling fraud aligns with the Trump administration’s focus on promoting efficiency and cutting out waste, as described by new CMS Administrator Mehmet Oz, MD.
-
2 months ago | 
ajmc.com | Hoangmai Pham |Christina Mattina
Am J Manag Care. 2025;31(4):In Press_____AJMC: How has the concept of managed care and the conversations around it changed over the past 30 years? PHAM: On the positive side, it has become a familiar way of life for American consumers, so there isn’t the vilification that had been going on in the 1990s.
-
2 months ago | 
ajmc.com | Christina Mattina
Neuromuscular disease researchers, clinicians, and advocates gathered to celebrate 75 years of progress at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas, Texas, but they also noted that these gains could be reversed if cuts to Medicaid and research funding proceed.
-
2 months ago | 
ajmc.com | Christina Mattina
Results from the phase 3 STEER study of intrathecal onasemnogene abeparvovec showed encouraging efficacy and safety data for children aged 2 to 17 years with spinal muscular atrophy (SMA), paving the way for much broader uptake of this disease-modifying gene therapy.1 The findings were presented in a late-breaking research session of the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas, Texas, held March 16-19, 2025.
